Jul 10, 2020 4:05pm EDT Qualigen Therapeutics, Inc. Announces Closing of $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Jul 08, 2020 5:19pm EDT Qualigen Therapeutics, Inc. Announces $8 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Jul 07, 2020 8:00am EDT Qualigen Therapeutics Engages NFL Hall of Famer Mike Haynes as Advisor to the Company and Spokesman for the FastPack® Rapid Diagnostic System "Which Saved My Life"
Jul 01, 2020 8:00am EDT Qualigen Therapeutics Submits Notification to FDA to Commence Distribution of its FastPack® COVID-19 Antibody Test
Jun 10, 2020 8:00am EDT Qualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville, Plans to Develop AS1411 for the Treatment of COVID-19
Jun 04, 2020 8:00am EDT Qualigen Therapeutics Receives U.S. Patent Notice of Allowance for its STARS™ Technology
Jun 02, 2020 8:00am EDT Qualigen Therapeutics Releases FastPack® SARS-CoV-2 Antibody Diagnostic Test to University of Louisville to Conduct Validation Studies
Feb 04, 2020 2:33pm EST Qualigen Announces New U.S. Patent Issued for its FastPack® Diagnostic Technology
Apr 11, 2019 1:37pm EDT Qualigen Enters into Research Agreement for RAS Inhibitor Cancer Drug with University of Louisville (UofL)
